Allergies News and Research

Latest Allergies News and Research

Nuvaxovid COVID-19 vaccine given regulatory approval By MHRA

Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA).

3 Feb 2022

NIAID's new pandemic preparedness efforts aim to characterize prototype and priority pathogens

As the global COVID-19 pandemic continues into its third year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is focusing on preparing for a range of other viral threats that could cause a public health emergency.

2 Feb 2022

Study assesses the antibody response to additional dose of COVID-19 vaccine in transplant recipients

A study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication.

31 Jan 2022

Vaccine hypersensitivity in children

A new paper published in Pediatric Allergy and Immunity provides a useful overview of such reactions in relation to pediatric vaccines.

31 Jan 2022

Intranasal vaccine with nanoparticles offers strong protection against influenza viruses

An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

29 Jan 2022

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

In adults who had previously received a full regimen of a COVID-19 vaccine approved or authorized by the Food and Drug Administration (FDA), an additional dose of any of these COVID-19 vaccines was safe and prompted an immune response, according to study findings published Jan. 26 in The New England Journal of Medicine.

28 Jan 2022

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

24 Jan 2022

Study could offer a novel strategy to fight respiratory syncytial virus and coronaviruses

A new approach that targets the cellular machinery that viruses need to reproduce – rather than the virus itself – appears to stem replication of a common childhood pathogen known as respiratory syncytial virus (RSV), UT Southwestern researchers report in a new study.

24 Jan 2022

MU researchers identify highly prevalent mutations specific to Omicron variant

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant's high rate of infection.

22 Jan 2022

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years.

21 Jan 2022

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

The majority of young children treated with peanut immunotherapy achieved desensitization after two and a half years of treatment, and one in five remained in remission 26 weeks after treatment ended, according to a randomized controlled trial published in The Lancet.

20 Jan 2022

SARS-CoV-2 breakthrough infections elicit potent neutralizing antibody responses

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2.

20 Jan 2022

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

In a new study, scientists focused on the SARS-CoV-2 Beta variant and used computational methods to design and develop effective glycoprotein multi-epitope subunit vaccine candidates, based on the old and the new Beta virus strains.

20 Jan 2022

Schoolchildren in Hong Kong surveyed on the prevalence and impact of allergic diseases

A collaborative study by the Department of Social Work and Social Administration, the University of Hong Kong andthe Department of Paediatrics and Adolescent Medicine, United Christian Hospital

19 Jan 2022

New method reverses insecticide resistance using CRISPR/Cas9 technology

Insecticides play a central role in efforts to counter global impacts of mosquito-spread malaria and other diseases, which cause an estimated 750,000 deaths each year. These insect-specific chemicals, which cost more than $100 million to develop and bring to market, also are critical to controlling insect-driven damage on crops that poses a challenge to food security.

18 Jan 2022

Respiratory viruses lacking NS2 protein can be destroyed by the body's immune response

One viral protein could provide information to deter pneumonia causing the body's exaggerated inflammatory response to respiratory viruses, including the virus that causes COVID-19.

18 Jan 2022

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

In a new study, a team of researchers conducted a case-control study at a mass vaccination center in Japan to evaluate acute and long-term adverse events following immunization (AEFI) with coronavirus disease 2019 (COVID-19) Moderna vaccine.

17 Jan 2022

New technique could allow more diseases to be safely treated by nanomedicine

Researchers at Penn Medicine have discovered a new, more effective method of preventing the body's own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy's effectiveness.

11 Jan 2022

Allergies News and Research

Latest Allergies News and Research

Nuvaxovid COVID-19 vaccine given regulatory approval By MHRA

NIAID's new pandemic preparedness efforts aim to characterize prototype and priority pathogens

Study assesses the antibody response to additional dose of COVID-19 vaccine in transplant recipients

Vaccine hypersensitivity in children

Intranasal vaccine with nanoparticles offers strong protection against influenza viruses

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Study could offer a novel strategy to fight respiratory syncytial virus and coronaviruses

MU researchers identify highly prevalent mutations specific to Omicron variant

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

SARS-CoV-2 breakthrough infections elicit potent neutralizing antibody responses

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

Schoolchildren in Hong Kong surveyed on the prevalence and impact of allergic diseases

New method reverses insecticide resistance using CRISPR/Cas9 technology

Respiratory viruses lacking NS2 protein can be destroyed by the body's immune response

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

New technique could allow more diseases to be safely treated by nanomedicine

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Allergies News and Research

Latest Allergies News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in